Dimensional Fund Advisors LP bought a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 40,563 shares of the biopharmaceutical company’s stock, valued at approximately $474,000. Dimensional Fund Advisors LP owned approximately 0.12% of Bellicum Pharmaceuticals at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Nationwide Fund Advisors grew its position in Bellicum Pharmaceuticals by 30.4% during the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares during the last quarter. ProShare Advisors LLC grew its position in Bellicum Pharmaceuticals by 14.9% during the second quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 2,513 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Bellicum Pharmaceuticals during the second quarter valued at approximately $234,000. New York State Common Retirement Fund grew its position in Bellicum Pharmaceuticals by 30.8% during the second quarter. New York State Common Retirement Fund now owns 28,000 shares of the biopharmaceutical company’s stock valued at $327,000 after acquiring an additional 6,599 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Bellicum Pharmaceuticals by 31.0% during the second quarter. Rhumbline Advisers now owns 30,668 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 7,249 shares during the last quarter. 55.50% of the stock is currently owned by institutional investors and hedge funds.
Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at $9.59 on Wednesday. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals, Inc. has a 52-week low of $7.41 and a 52-week high of $18.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter last year, the business earned ($0.66) earnings per share. The business’s revenue was up 18.2% on a year-over-year basis. research analysts forecast that Bellicum Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.
In other news, CFO Alan A. Musso sold 6,206 shares of the firm’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 18.77% of the stock is currently owned by company insiders.
BLCM has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Raymond James Financial set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group reiterated a “buy” rating and set a $16.00 price target (down from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. ValuEngine cut shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, August 11th. Finally, BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $26.20.
COPYRIGHT VIOLATION WARNING: “40,563 Shares in Bellicum Pharmaceuticals, Inc. (BLCM) Purchased by Dimensional Fund Advisors LP” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://ledgergazette.com/2017/12/06/40563-shares-in-bellicum-pharmaceuticals-inc-blcm-purchased-by-dimensional-fund-advisors-lp.html.
Bellicum Pharmaceuticals Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.